Hims & Hers Health Forecast Jumps 8% on Analyst Upgrades
Can analyst optimism outweigh FDA peptide uncertainty in the Hims & Hers Health Forecast after an 8% stock surge?
Hims & Hers peptide regulation: +10.5% rally tests FDA bet
Is the latest FDA shift on peptides turning Hims & Hers into a long-term growth story or just fueling a speculative spike?
Hims & Hers GLP-1 partnership sparks new weight-loss boom
Can the Hims & Hers GLP-1 partnership with Novo Nordisk turn telehealth weight loss into the company’s next major growth engine?
Hims & Hers insider transactions Warning as GLP-1 bets grow
Are Hims & Hers insider transactions hinting at caution just as the company doubles down on its high-stakes GLP-1 obesity strategy?
Hims & Hers Novo Nordisk deal sparks 44% premarket surge
Can the new Hims & Hers Novo Nordisk deal really turn an 80% stock collapse into a long-term GLP-1 comeback story? How big is the market reaction to…